重组B亚单位/菌体霍乱疫苗以抗酸剂冲服在2~6岁健康人群中的免疫原性与安全性研究
2009年12月至2010年1月在广西崇左招募900名2~6岁儿童,按2∶1随机双盲安慰剂对照接种以抗酸剂冲服的重组B亚单位/菌体霍乱疫苗。免疫后试验组抗-CT与抗-Vab的2倍增长率分别为90.96%和57.63%,均高于安慰剂组的15.73%和29.21%;两组不良反应发生率分别为37.67%(226/600)和36.67%(110/300),程度主要为1级。结论认为该疫苗用抗酸剂服法能产生良好免疫应答且有较好安全性。
要点
- 2~6岁儿童按2∶1随机双盲安慰剂对照,试验组600例、安慰剂组300例。
- 免疫后抗-CT与抗-Vab的2倍增长率试验组分别为90.96%、57.63%,高于安慰剂组的15.73%、29.21%。
- 不良反应发生率试验组37.67%(226/600)与安慰剂组36.67%(110/300),程度主要为1级。
核心结论
- 重组B亚单位/菌体霍乱疫苗以抗酸剂冲服能够产生良好的免疫应答,且有较好的安全性。
研究设计与样本
- 随机、双盲、安慰剂对照试验,于2009年12月至2010年1月在广西崇左辖区各疫苗接种点招募2~6岁健康儿童900名,按2∶1随机接受以抗酸剂冲服霍乱疫苗(试验组)或安慰剂(安慰剂组)。
- 免疫原性亚组采集首剂免疫前及第49天(±3 d)血样,最终具有免疫前后配对血清者266例(试验组177例,安慰剂组89例)。
主要发现
- 900名对象中男503名、女397名(试验组335名与265名,安慰剂组168名与132名),入组年龄试验组(4.8±1.2)岁、安慰剂组(4.9±1.2)岁,两组性别及年龄构成差异均无统计学意义(χ²=0.00,P=1.000;t=0.55,P=0.585)。
- 免疫后试验组抗-CT与抗-Vab的2倍增长率分别为90.96%、57.63%,均高于安慰剂组的15.73%和29.21%(χ²值分别为15.89和3.85,P值均<0.001)。
- 免疫后试验组抗-CT与抗-Vab的GMT分别为1∶647.56、1∶16.19,安慰剂组分别为1∶99.49和1∶11.27(t值分别为15.82和3.43,P值均<0.05)。
- 试验组抗-CT与抗-Vab的GMT较免疫前分别增长6.63倍和1.64倍,安慰剂组分别增长1.11倍和1.16倍(t'值分别为17.85和4.96,P值均<0.001)。
- 试验组与安慰剂组不良反应发生率分别为37.67%(226/600)和36.67%(110/300),主要不良反应有发热、恶心、呕吐、腹痛、腹泻、头痛、乏力、过敏、皮疹等,程度主要为轻度(1级)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To assess the immunogenicity and safety of recombinant B-subunit/whole cell cholera vaccine (rBS/WC) oral cholera vaccine (Ora Vacs) infused with antacids in healthy population at ages of 2-6 years. Methods: Between December 2009 and January 2010, we recruited 900 volunteers aged 2-6 years od through giving out recruitment notice for the eligible children's parents from different vaccination clinics of Chongzuo city in Guangxi Zhuang Autonomous Region. This study was a randomized, double-blind, placebo-controlled trial, and subjects were randomly (2∶1) assigned to receive Cholera vaccine infused with antacids or placebo, and observed for safety. Serum samples of 300 subjects in immunogenicity subgroups (200 for vaccine groups, 100 for control groups) before the 1st dose and 49 d (±3 d) after immunization were collected, and determined for antibody levels against the cholera toxin (anti-CT) and cholera vibriocidal (anti-Vab) with Enzyme-linked immunosorbent assays (ELISA), based on which the GMT was calculated. There were 266 cases paired with the serum samples before and after immunization (177 for vaccine groups, 89 for control groups). The comparison of subjects' age at enrollment and the level of GMT before and after immunization between groups were analyzed by t test. The superiority test for the difference between seroconversion rates of vaccine groups and control groups were analyzed by χ(2) test. Results: Of 900 subjects enrolled, the number of males and females were 503 and 397 respectively (vaccine groups 335 vs. 265, control groups 168 vs. 132), the average ages of vaccine groups and control groups at enrollment were (4.8±1.2) years and (4.9±1.2) years respectively. There were no significant differences between groups in terms of gender and age (χ(2)=0.00, P=1.000; t=0.55, P=0.585). The 2 times increase rates of anti-CT and anti-Vab in vaccine groups after inoculation were 90.96% and 57.63% respectively, which were superiority to those of control groups (15.73% and 29.21%), and significant differences were observed between groups (χ(2)=15.89, χ(2)=3.85, P<0.001). There were significant differences between vaccine groups and control groups after inoculation in terms of GMTs of anti-CT (1∶647.56 vs. 1∶99.49) and anti-Vab antibodies (1∶16.19 vs. 1∶11.27) (t values were 15.82 and 3.43, respetively; both P values were<0.05), significant differences were observed in the growth rates when compared the GMTs of anti-CT (6.63 vs. 1.11) and anti-Vab antibodies (1.64 vs. 1.16) before inoculation between vaccine groups and control groups (t'=17.85 and 4.96, P<0.001). In terms of safety, the adverse reaction rates in vaccine groups and control groups were 37.67% (226/600) and 36.67% (110/300), respectively,the common adverse reaction including fever, nausea, vomiting, abdominal pain, diarrhea, headache, fatigue, allergies, rash, etc; and the severity degree were mainly for level 1. Conclusion: Ora Vacs infused with antacids could produce an positive effect on immune response and safety. 目的: 评价重组B亚单位/菌体霍乱疫苗在2~6岁健康人群中的免疫原性和安全性。 方法: 于2009年12月至2010年1月,采用发放招募通知的方法,在广西崇左辖区内的各疫苗接种点招募2~6岁儿童家长,共900名。采用随机、双盲、安慰剂对照的设计,将其按2∶1的比例随机接受以抗酸剂冲服霍乱疫苗(试验组)或安慰剂(安慰剂组)。采集入组的前300例(试验组200例,安慰剂组100例)对象首剂免疫前后第49天(±3 d)的血样,用ELISA检测血清中的抗霍乱毒素抗体(抗-CT)与杀弧菌抗体(抗-Vab)几何平均滴度(GMT),最终具有免疫前后配对血清者有266例(试验组177例,安慰剂组89例)。采用t比较两组对象入组时的年龄和免疫前后GMT水平差异;采用χ(2)检验比较两组性别构成、不良反应发生率以及抗体阳转率的率差差异。 结果: 900名调查对象中,男、女人数分别为503和397名(试验组为335和265名,对照组为168和132名),入组时试验组年龄为(4.8±1.2)岁,安慰剂组为(4.9±1.2)岁,两组间性别及年龄构成差异均无统计学意义(χ(2)=0.00,P=1.000;t=0.55,P=0.585)。免疫后试验组抗-CT与抗-Vab的2倍增长率分别为90.96%、57.63%,均高于安慰剂组的15.73%和29.21%(χ(2)值分别为15.89和3.85,P值均<0.001)。免疫后试验组抗-CT与抗-Vab的GMT水平分别为1∶647.56、1∶16.19,安慰剂组分别为1∶99.49和1∶11.27(t值分别为15.82和3.43,P值均<0.05),试验组较免疫前增长6.63和1.64倍,安慰剂组增长1.11和1.16倍(t'值分别为17.85和4.96,P值均<0.001)。试验组与安慰剂组不良反应发生率分别为37.67%(226/600)、36.67%(110/300),主要不良反应有发热、恶心、呕吐、腹痛、腹泻、头痛、乏力、过敏、皮疹等,程度主要为轻度(1级)。 结论: 重组B亚单位/菌体霍乱疫苗,用抗酸剂服法能够产生良好的免疫应答,且有较好的安全性。.
引用
- Huang T, Li RC, Liu DP, et al. [Study on the immunogenicity and safety of recombinant B-subunit/whole cell cholera vaccine infused with antacids in healthy population at ages of 2-6 years]. Zhonghua Yu Fang Yi Xue Za Zhi. 2017. PMID: 28881549. doi:10.3760/cma.j.issn.0253-9624.2017.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。